Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-24

Clinical Trial Update: Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action [Phase 4]

View source ↗

Summary

A Phase 4 trial update provides new insights into migraine pathophysiology and the mechanism of action of galcanezumab, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Emgality (galcanezumab)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Chronic Migraine | Phase 4 | Status: COMPLETED | Results posted: 2026-03-24